February 8, 2019
PALO ALTO, Calif., Feb. 8, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that a presentation on its investigational therapy KSI-301 will be made at the Angiogenesis, Exudation, and Degeneration 2019 meeting being held on February 9, 2019 in Miami, FL.
“The data being presented at Angiogenesis 2019 will illustrate in more detail the safety and durability through 12 weeks of a single dose of KSI-301 in patients with diabetic macular edema. As previously reported, no dose-limiting toxicities, drug-related adverse events or intraocular inflammation were observed, and rapid, high-magnitude, and durable treatment responses were seen at all dose levels tested,” said Jason Ehrlich, M.D., Ph.D., Kodiak’s Chief Medical Officer and Chief Development Officer. “These results support our robust clinical plan for KSI-301, including a Phase 1b study that is currently recruiting patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, and our upcoming Phase 2 study in patients with wet AMD.”
Details of the presentation are as follows:
Title: KSI-301: Update on Phase 1 Studies with a First in Class Antibody-Biopolymer Conjugate for Treatment of Wet AMD, DME, and Other Retinal Vascular Diseases Presenter: Diana V. Do, MD, Professor of Ophthalmology at Stanford University School of Medicine and Chair of the Kodiak clinical advisory board Presentation date and time: February 9; 2:30 – 2:40 PM ET
Dr. Do’s slide presentation will be available on the Kodiak Investor Relations website at http://ir.kodiak.com/ following completion of her presentation.
KSI-301 is an investigational therapy built on the Company’s ABC PlatformTM. It is designed to maintain potent and effective drug levels in ocular tissues for longer than existing agents. Kodiak’s objective with KSI-301 is to improve real-world outcomes for patients with macular degeneration and diabetic macular edema and to enable earlier treatment and prevention of vision loss for patients with diabetic eye disease.
About Kodiak Sciences Inc.
Kodiak Sciences is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Our Antibody Biopolymer Conjugate, or ABC, Platform merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak’s discovery engine. In addition to its lead product candidate, KSI-301, a novel anti-VEGF antibody biopolymer conjugate in clinical development for the treatment of age-related macular degeneration and diabetic retinopathy, Kodiak has leveraged its ABC PlatformTM to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF bioconjugate for the treatment of neovascular retinal diseases such as wet AMD and diabetic retinopathy. Kodiak is based in Palo Alto, CA. For more information, visit localhos:8080.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding our platform technology and potential therapies, future development plans, clinical and regulatory objectives and the timing thereof, anticipated design of planned clinical trials, expectations regarding the potential efficacy and commercial potential of our product candidates, including KSI-301, the anticipated presentation of data, the results of our research and development efforts and our ability to advance our product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “pursue,” and other similar expressions among others. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the preliminary safety, efficacy and durability data for our KSI-301 product candidate from the Phase 1 study will not continue or persist; cessation or delay of any of the ongoing clinical studies and/or our development of KSI-301 may occur; future potential regulatory milestones of KSI-301, including those related to current and planned clinical studies may be insufficient to support regulatory submissions or approval; anticipated presentation of data at upcoming conferences may not occur; our research and development efforts and our ability to advance our product candidates into later stages of development may fail; any one or more of our product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Kodiak undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward- looking statements.
“Kodiak,” “ABC Platform” and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various jurisdictions.
View original content:http://www.prnewswire.com/news-releases/kodiak-sciences-announces-upcoming-presentation-of-ksi-301-12-week-phase- 1a-study-data-at-angiogenesis-exudation-and-degeneration-2019-meeting-300792237.html
SOURCE Kodiak Sciences Inc.
John Borgeson, Senior Vice President and Chief Financial Officer, Tel (650) 281-0850, email@example.com